Abcam - the next giant of the Life Sciences?

Thursday, Apr 07 2011 by
17
Abcam  the next giant of the Life Sciences

Abcam (LON:ABC) was founded in a Cambridge research lab in 1998 with the simple idea of making it easier for research scientists to buy antibodies across the web. From those humble beginnings it has become one of the AIM market's most notable success stories with a share price that has grown eightfold since float to a market capitalisation of almost £700m. Abcam now runs three websites and has grown its catalogue to list 69,000 products, extended operations to the US, China and Japan while selling its products globally.

With the similarities in its online distribution business model, Abcam has been labelled by some as the 'Amazon of Antibodies', but in contrast to the book-selling behemoth, Abcam has enjoyed consistently high margins and returns on capital. These figures have grown impressively every year since float in spite of operating in what any internet search will show to be an extremely competitive market place.

 While Abcam has grown by seizing market share, it has also nurtured and grown demand through a focus on collecting the most valuable asset that scientists require - the data rich information that surrounds each of the antibodies it sells. As Jonathan Milner, CEO, explains below, it turns out that the real reason why Abcam has sustained its competitive advantage is because these data sheets are unique to Abcam and are impossible for competitors to duplicate. As a result, Abcam is in the position where their oldest range of products now command the highest prices in a catalogue which grows in breadth every year.

Some brokers have questioned whether Abcam's business model can continue to grow at its historic pace as the business matures while others have worried that government austerity measures will impact budgets for medical research spending. But in spite of this, Jonathan Milner believes the opportunities available to Abcam are huge and has the dream of building the company into a giant of the life sciences. With the valuation now reaching a PE ratio of 27 times forecast earnings, there are plenty investors that are backing Abcam to deliver.

The company recently released interim results with pre-tax profits up 35.4% to £15.2m on sales of almost £40m. Strong cash generation has taken cash on hand to £47m providing a warchest for possible acquisitions.

Jonathan, could you introduce Abcam for those readers that don't know the story?

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested. ?>


Do you like this Post?
Yes
No
17 thumbs up
0 thumbs down
Share this post with friends



Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support. more »

LSE Price
1178p
Change
0.3%
Mkt Cap (£m)
2,427
P/E (fwd)
34.3
Yield (fwd)
1.1



  Is LON:ABC fundamentally strong or weak? Find out More »


What's your view on this article? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis